Table 2. . Demographic and outcome data of patients treated with WP1066.

Enrollment number	Dose level (mg/kg)	Age at Dx	KPS	Tumor characteristics					PFS	MRI response	Reason off study	Survival weeks
				Histology	IDH1 mutant	MGMT	p-STAT3	CD3
1	1	59	90	GBM	Negative	Negative	2.6%	8.0%	13 w, 5 d	PD	PD	Alive
2	2	46	100	GBM	Positive	Positive	4.3%	0.3%	11 w, 4 d	PD	PD	65
3	4	34	100	GBM	Negative	Indeterminant	2.3%	0.3%	10 w, 6 d	PD	PD	108
4	4	55	90	GBM	Negative	Negative	6.0%	3.0%	9 w, 2 d	PD	PD	109
5	4	38	70	GBM	Negative	Positive	9.6%	2.0%	10 w, 4 d	PD	PD	194
6	8	56	90	GBM	Positive	Positive	0.6%	0.7%	3 w, 3 d	N/A	Withdraw	Alive
7	8	45	90	GBM	Negative	Indeterminant	7.9%	5.4%	6 w, 4 d	PD	PD	115
8	8	56	80	AA	Positive	Negative	3.2%	2.2%	7 w, 4 d	PD	PD	98

AA: Anaplastic astrocytoma; d: Day; Dx: Diagnosis; GBM: Glioblastoma; KPS: Karnofsky Performance Scale Score; PD: Progressive disease; PFS: Progression-free survival; w: Week.